Types of Multiple Myeloma

Key Takeaways

• Multiple myeloma is classified largely by the type of abnormal immunoglobulin (antibody) protein that the cancerous plasma cells produce.
• IgG and IgA are the immunoglobulin classes most often identified in multiple myeloma; rarer patterns include IgD, IgE, and IgM.
• Light chain multiple myeloma is a significant variant in which plasma cells produce only free light chains rather than a complete antibody, a pattern linked to a higher risk of kidney complications.
• Smoldering myeloma is an asymptomatic precursor state, distinct from the earlier precursor MGUS, that is monitored rather than treated immediately in most cases.
• Classification by immunoglobulin type, light chain status, and genetic findings directly shapes treatment planning and monitoring strategy.

Main Types of Multiple Myeloma by Protein Class

Multiple myeloma subtypes and classifications are largely defined by the type of immunoglobulin (antibody) that the malignant plasma cells overproduce. Normal plasma cells produce complete antibodies made up of heavy chains and light chains. In myeloma, this production becomes dysregulated, generating a specific abnormal protein — known as an M protein or paraprotein — that serves as a diagnostic and classification marker.

The immunoglobulin type is used both to help diagnose the disease and to choose which laboratory tests are used to track it over time. IgG and IgA are the classes most often identified in multiple myeloma testing. IgA levels can be harder to quantify on standard serum protein testing than IgG and sometimes require immunofixation electrophoresis for accurate tracking. Less commonly, plasma cells produce only free light chains rather than a complete antibody, or, more rarely, immunoglobulin D (IgD) or immunoglobulin E (IgE).

IgM myeloma is also rare, and it is important not to confuse it with Waldenström macroglobulinemia. Although both conditions involve an IgM protein, Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma — a completely separate disease from multiple myeloma, arising from a different lymphoid cell line and managed with its own treatment approach. Careful laboratory and pathology evaluation is needed to tell the two conditions apart.

Light Chain Multiple Myeloma and Other Variant Subtypes

Light chain multiple myeloma vs other types represents one of the most clinically significant distinctions in myeloma classification. In this subtype, malignant plasma cells produce only free light chains — either kappa (κ) or lambda (λ) — rather than complete immunoglobulin molecules. Because free light chains are small molecules, they pass readily through the kidney’s filtering structures and can accumulate there, making kidney damage a leading complication in this group.

Patients with light chain myeloma may have little or no M protein detectable on standard serum protein electrophoresis, which can complicate initial diagnosis. Diagnosis instead relies on serum free light chain assays and urine tests for Bence Jones protein. The kappa-to-lambda free light chain ratio is a key monitoring tool throughout treatment in this subtype. Patients may also experience amyloidosis — a condition in which misfolded light chain proteins build up in organs, including the kidneys, heart, and peripheral nerves.

Another variant worth noting is non-secretory myeloma, in which plasma cells release little or no detectable M protein into the blood or urine. This subtype requires bone marrow biopsy and imaging — including PET-CT or MRI — for accurate assessment of disease burden. Because a detectable paraprotein is absent, non-secretory myeloma is generally monitored using imaging and marrow findings rather than M protein trends, with treatment approaches comparable to those used for secretory subtypes.

Smoldering vs. Active Multiple Myeloma: Key Differences

Smoldering multiple myeloma vs active myeloma is a distinction that significantly affects clinical management. According to the National Cancer Institute, smoldering multiple myeloma (SMM) is an intermediate, asymptomatic stage characterized by elevated M protein levels and clonal bone marrow plasma cells typically in the 10% to 60% range, but without the organ damage that defines active disease. Active myeloma, by contrast, is defined by the presence of myeloma-related organ or tissue impairment, most often elevated blood calcium, reduced kidney function, anemia, or bone lesions.

The risk of SMM progressing to active myeloma varies considerably and depends on several laboratory findings together, including the M protein level, the free light chain ratio, how many plasma cells are found on a bone marrow sample, and certain chromosomal changes. NCI data indicate that patients with several of these high-risk features can have a greater than 50% chance of progressing to active myeloma within two years, while patients with fewer risk factors may remain stable for considerably longer. Because of this variability, risk-stratification models help clinicians identify which patients with SMM may benefit from closer monitoring or, in select high-risk cases, earlier intervention.

Beyond SMM, it is important to distinguish myeloma from its earlier precursor, monoclonal gammopathy of undetermined significance (MGUS). According to NCI data, MGUS involves M protein levels lower than those used to define smoldering myeloma (generally under 3 g/dL) and fewer than 10% plasma cells in the bone marrow, with no organ damage. The annual risk of MGUS progressing to myeloma or a related blood disorder is roughly 0.5% to 1% in most patients, though this risk is higher in those with additional risk factors. Regular monitoring is essential for both MGUS and SMM to detect any transition to active disease promptly.

How Multiple Myeloma Classifications Guide Treatment

Multiple myeloma classifications guide treatment by determining which therapeutic agents, monitoring strategies, and risk-adapted approaches are most appropriate for each patient. The immunoglobulin subtype, genetic and chromosomal findings, and disease stage each contribute to individualized treatment planning. For example, patients with high-risk chromosomal changes — such as deletion 17p or translocation t(4;14) — may require more intensive regimens or novel agent combinations compared to patients with standard-risk disease.

The distinction between IgG and IgA multiple myeloma extends into treatment monitoring. IgG myeloma is generally tracked using standard serum M protein measurement, while IgA levels can be harder to quantify on the same test and may require immunofixation electrophoresis for accurate tracking. Similarly, light chain-only disease is monitored with serum free light chain testing rather than traditional M protein measurement, making subtype classification central to choosing the right monitoring approach during therapy.

Staging systems also intersect with classification. The Revised International Staging System combines beta-2 microglobulin and albumin levels with lactate dehydrogenase and chromosomal findings to assign patients to Stage I, II, or III, each associated with a different typical course. Smoldering myeloma is not staged using this system in clinical practice; instead, it is risk-stratified separately using the laboratory findings described above. Taken together, these classification frameworks allow the care team to tailor induction therapy, consolidation, maintenance, and transplant-eligibility decisions to each patient’s disease biology.

Frequently Asked Questions

Is multiple myeloma always the same disease regardless of subtype?

No. Different types of multiple myeloma behave somewhat differently and can call for individualized approaches. Classification based on immunoglobulin class, light chain status, and chromosomal findings can influence prognosis and treatment selection — for example, light chain-only disease carries a comparatively higher risk of kidney complications than some other subtypes. This is one reason accurate subtype identification is a foundational step in a patient’s care plan.

Can smoldering myeloma be treated, or only monitored?

Traditionally, smoldering myeloma has been managed with active monitoring alone, without treatment. Clinical trial data reviewed by the National Cancer Institute indicate that starting therapy early in carefully selected high-risk patients can meaningfully delay progression to active disease. Treatment decisions depend on individual risk stratification, so patients classified as high-risk should discuss the potential benefits and risks of early intervention with their hematology care team.

Are there types of multiple myeloma that are harder to diagnose?

Yes. Non-secretory myeloma and IgD myeloma are among the more diagnostically challenging subtypes, since both can be missed or delayed on standard laboratory testing and sometimes require bone marrow biopsy or imaging for confirmation. Light chain myeloma can also be missed without serum free light chain assays, underscoring the importance of comprehensive laboratory evaluation in suspected myeloma cases.

Sources

• National Cancer Institute – Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Patient Version
• National Cancer Institute – Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)–Health Professional Version
• MedlinePlus – Multiple Myeloma: MedlinePlus Genetics
• MedlinePlus – Multiple Myeloma: MedlinePlus Medical Encyclopedia